Latest News - Merck KGaA
Top Corporates Hub
Merck KGaA
The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI
08.09.2026 01:49
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.
Could Merck (MRK) Change Cholesterol Treatment With The First Oral PCSK9 Pill?
04.09.2026 17:09
Merck (NYSE:MRK) received FDA approval for LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor for hypercholesterolemia. The new therapy offers a pill-based alternative to existing injectable PCSK9 treatments for patients with high cholesterol. The approval introduces a new segment in cholesterol management that other drug companies are also targeting with oral PCSK9 candidates. For a broader view of where drug development and data driven medicine intersect, explore other healthcare...
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
04.09.2026 14:37
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170
04.09.2026 10:27
Wells Fargo analyst Mohit Bansal maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $170.
Moderna: Massive Asymmetry About What The mRNA Is!
03.09.2026 06:36
Moderna's upside hinges on Intismeranâs ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.
Global Health Leader Jeffrey L. Sturchio, PhD, Joins FINN Partners' Health Policy and Impact Group as Senior Advisor
02.09.2026 14:00
FINN Partners, one of the world's largest independent communication, public affairs and marketing firms, today announced that Jeffrey L. Sturchio, PhD, is joining as a senior adviser. He will be part of FINN's Global Health Practice and work with the Health Policy and Impact Group. Dr. Sturchio's appointment strengthens a multinational team whose expertise spans health policy, stakeholder engagement, communications and purpose, adding one of global health's most respected advisors to its ranks.
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
02.09.2026 11:45
RAHWAY, N.J., September 02, 2026--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
26.08.2026 08:31
Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.
Mike Johnson Says Prescription Drug Prices Are at 'Lowest Levels' in 60 Years, Credits Trump and Republicans for Lower Costs
26.08.2026 03:56
Johnson credits Trump and Republicans for record low drug prices, stating Americans are seeing lower costs and more money in their pockets.
Moderna Stock Edges Higher Tuesday: What's Happening?
25.08.2026 09:18
Shares of Moderna are trading higher Tuesday morning, as Wall Street analysts upgrade their ratings following landmark Phase 3 oncology data.
Regeneron: Why I Still See Upside After The Rally
25.08.2026 09:01
Regeneron Pharmaceuticals, Inc. stock outlook: Eylea pressure eases as Dupixent jumps; FDA OKs Pasatru. Read why REGN stock is a buy.
Argus Research Maintains Buy on Merck & Co, Raises Price Target to $170
25.08.2026 08:58
Argus Research analyst Jasper Hellweg maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $145 to $170.
Court Rejects Merck’s Challenge to Medicare Drug Price Negotiation Program
25.08.2026 08:52
Court rejects Merck's lawsuit against Medicare drug price negotiations. Penalties for noncompliance include steep excise taxes.
Why Tempus AI Skyrocketed This Week
23.08.2026 12:35
Tempus AI's latest acquisition is looking like a great move.
Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical
22.08.2026 08:53
Check out the companies making headlines this week:
ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’
22.08.2026 01:19
ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.
XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)
20.08.2026 14:25
Buy XBI now: SPDR S&P Biotech ETF up 34% since March on M&A and trial catalysts.
This Allstate Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
20.08.2026 12:01
Wall Street analysts changed outlook on top names. Check all rating changes, including upgrades/downgrades, on Benzinga analyst ratings page.
This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
20.08.2026 08:50
Wall Street analysts upgraded PGR, MRK, EPR and initiated coverage on BEKE and IONS. Check analyst ratings and price targets for these stocks.
Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
20.08.2026 08:19
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.